Literature DB >> 22023887

Central nervous system atypical teratoid rhabdoid tumours: the Canadian Paediatric Brain Tumour Consortium experience.

L Lafay-Cousin1, C Hawkins, A S Carret, D Johnston, S Zelcer, B Wilson, N Jabado, K Scheinemann, D Eisenstat, C Fryer, A Fleming, C Mpofu, V Larouche, D Strother, E Bouffet, A Huang.   

Abstract

BACKGROUND: Atypical teratoid rhabdoid tumours (ATRT) are aggressive brain tumours mostly occurring in early childhood. Largest published series arise from registries and institutional experiences (1-4). The aim of this report is to provide population-based data to further characterise this rare entity and to delineate prognostic factors. PATIENTS AND METHODS: A national retrospective study of children ⩽18years diagnosed with a central nervous system (CNS) ATRT between 1995 and 2007 was undertaken. All cases underwent central pathology review.
RESULTS: There were 50 patients (31 males; median age at diagnosis of 16.7months). Twelve patients were >36months. Infratentorial location accounted for 52% of all cases. Nineteen patients (38%) had metastatic disease. Fifteen (30%) underwent gross total resection (GTR). Ten patients (20%) underwent palliation. Among the 40 remaining patients, 22 received conventional chemotherapy and 18 received high dose chemotherapy regimens (HDC); nine received intrathecal chemotherapy and 15 received adjuvant radiation. Thirty of the 40 treated patients relapsed/progressed at a median time of 5.5months (0-32). The median survival time of the entire cohort was 13.5months (1-117.5months). Age, tumour location and metastatic status were not prognostic. Patients with GTR had a better survival (2years overall survival (OS): 60%±12.6 versus 21.7%±8.5, p=0.03). HDC conferred better outcome (2years OS 47.9%±12.1 versus 27.3%±9.5, p=0.036). Upfront radiation did not provide survival benefit. Six of the 12 survivors (50%) did not receive radiation.
CONCLUSION: The outcome of CNS ATRT remains poor. However, the use of HDC provides encouraging results. GTR is a significant prognostic factor. The role of adjuvant radiation remains unclear.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22023887     DOI: 10.1016/j.ejca.2011.09.005

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  65 in total

1.  Tumor control and QoL outcomes of very young children with atypical teratoid/rhabdoid tumor treated with focal only chemo-radiation therapy using pencil beam scanning proton therapy.

Authors:  Damien C Weber; Carmen Ares; Robert Malyapa; Francesca Albertini; Gabriele Calaminus; Ulrike Kliebsch; Lorentzos Mikroutsikos; Petra Morach; Alessandra Bolsi; Tony Lomax; Ralf Schneider
Journal:  J Neurooncol       Date:  2014-11-02       Impact factor: 4.130

Review 2.  Molecular insights into pediatric brain tumors have the potential to transform therapy.

Authors:  Amar Gajjar; Stefan M Pfister; Michael D Taylor; Richard J Gilbertson
Journal:  Clin Cancer Res       Date:  2014-11-15       Impact factor: 12.531

Review 3.  Biology and Treatment of Rhabdoid Tumor.

Authors:  James I Geller; Jacquelyn J Roth; Jaclyn A Biegel
Journal:  Crit Rev Oncog       Date:  2015

4.  Atypical teratoid rhabdoid tumor: long-term survival after chemoradiotherapy.

Authors:  Vivek Verma; Catrina P Johnson; Nathan R Bennion; Abhijeet R Bhirud; Sicong Li; Rodney D McComb; Chi Lin
Journal:  Childs Nerv Syst       Date:  2015-05-05       Impact factor: 1.475

5.  Overall Survival of Primary Intracranial Atypical Teratoid Rhabdoid Tumor Following Multimodal Treatment: A Pooled Analysis of Individual Patient Data.

Authors:  Xiu-Jian Ma; Da Li; Liang Wang; Shu-Yu Hao; Li-Wei Zhang; Jun-Ting Zhang; Zhen Wu
Journal:  Neurosurg Rev       Date:  2018-12-08       Impact factor: 3.042

6.  Embryonal tumors in Canadian children less than 36 months of age: results from the Canadian Pediatric Brain Tumor Consortium (CPBTC).

Authors:  E Story; D L Johnston; U Bartels; A S Carret; B Crooks; D D Eisenstat; C Fryer; L Lafay-Cousin; V Larouche; B Wilson; S Zelcer; M Silva; J Brossard; E Bouffet; D L Keene
Journal:  J Neurooncol       Date:  2017-05-16       Impact factor: 4.130

Review 7.  Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies.

Authors:  Michael C Frühwald; Jaclyn A Biegel; Franck Bourdeaut; Charles W M Roberts; Susan N Chi
Journal:  Neuro Oncol       Date:  2016-01-10       Impact factor: 12.300

8.  Multimodal treatments combined with gamma knife surgery for primary atypical teratoid/rhabdoid tumor of the central nervous system: a single-institute experience of 18 patients.

Authors:  Yan-Ming Ren; Xia Wu; Chao You; Yue-Kang Zhang; Qiang Li; Yan Ju
Journal:  Childs Nerv Syst       Date:  2017-12-07       Impact factor: 1.475

9.  Central nervous system tumors in the first year of life: a clinical and pathologic experience from a single cancer center.

Authors:  Maysa Al-Hussaini; Maisa Swaidan; Usama Al-Jumaily; Awni Musharbash
Journal:  Childs Nerv Syst       Date:  2013-03-24       Impact factor: 1.475

10.  The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type.

Authors:  Leora Witkowski; Catherine Goudie; Pilar Ramos; Talia Boshari; Jean-Sebastien Brunet; Anthony N Karnezis; Michel Longy; James A Knost; Emmanouil Saloustros; W Glenn McCluggage; Colin J R Stewart; William P D Hendricks; Heather Cunliffe; David G Huntsman; Patricia Pautier; Douglas A Levine; Jeffrey M Trent; Andrew Berchuck; Martin Hasselblatt; William D Foulkes
Journal:  Gynecol Oncol       Date:  2016-03-19       Impact factor: 5.482

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.